Mar 15, 2016

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

Proceed to the page: http://linkis.com/PkNBz

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent news-medical.net Articles

Latest Links Processed

0/120